@article{CDT5353,
author = {Julio F. Marchini and Wilton F. Gomes and Bruno Moulin and Marco A. Perin and Ludmilla A.R.R. Oliveira and J. Airton Arruda and Valter C. Lima and Antonio A.G. Lima and Paulo R.A. Caramori and Cesar R. Medeiros and Mauricio R. Barbosa and Fabio S. Brito Jr and Expedito E. Ribeiro and Pedro A. Lemos},
title = {Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial},
journal = {Cardiovascular Diagnosis and Therapy},
volume = {4},
number = {6},
year = {2014},
keywords = {},
abstract = {Background: Few studies have examined the very long-term outcomes after implantation of drug-eluting stents (DES) coated with biodegradable polymers (BP). This report presents the 5-year clinical follow-up of patients treated with BP-DES in the randomized PAINT trial.
Methods: The PAINT study is a prospective, multicenter randomized controlled trial that allocated 274 patients for treatment with two BP-DES formulations [paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES)] or bare metal stents (BMS) in a 1:2:2 ratio, respectively. The primary end-point of this sub-study was defined as the composite of the major cardiac adverse events (MACE) cardiac death, myocardial infarction (MI) or ischemia-driven target vessel revascularization (TVR) at 5 years.
Results: The 5-year MACE rates were different among the groups: 35.3%, 22.5% and 16.9% for BMS, PES and SES, respectively (P},
issn = {2223-3660}, url = {https://cdt.amegroups.org/article/view/5353}
}